Posted by Michael Wonder on 14 Aug 2024
Linzagolix choline for the treatment of patients with moderate to severe symptoms of uterine fibroids (final guidance)
14 August 2024 - NICE has published final evidence-based recommendations on the use of linzagolix choline (Yselty) for the treatment of adults with moderate to severe symptoms of fibroids.
Linzagolix choline is recommended as an option for the treatment of adults of reproductive age with moderate to severe symptoms of uterine fibroids only if it is intended to be used for longer-term treatment (normally for more than 6 months and not for people who need short-term treatment, for example, before planned surgery).
